CDN Connection Issue

It appears that your current network does not allow connection to the CDN (Content Delivery Network) required for this service to function properly.

To resolve this issue, please try the following actions :

• Contact your network administrator : Inform them of this restriction so they can adjust the network settings accordingly.

• Use another network : Try connecting from a different network, such as another Wi-Fi network or a mobile connection.

We apologize for the inconvenience and thank you for your understanding.

Welcome to the ADVANZ Digital Hub UK

You are about to enter uk.advanzdigitalhub.com. This is a promotional website pertaining to ADVANZ PHARMA Products. The contents of this website are intended for healthcare professionals in the UK only.

UK/MISC/PM/0024 March 2026
I am a :
home-logo
flag-logo
Country Selector
Selecting a new country will redirect you to our country selector page
Go to Country Selector
  • Home
  • About Us
  • Biosimilars
  • Product Information 
    • Men's Health
      • Tostran®
    • Hepatology
      • OCALIVA®▼
    • Anti-Infective
      • XYDALBA™
      • EXBLIFEP®▼
  • Prescribing Information 
    • OCALIVA®▼ (obeticholic acid) 5mg and 10 mg film-coated tablets
    • TOSTRAN® (testosterone) 20mg/g transdermal gel
    • XYDALBA™ (Dalbavancin hydrochloride) 500mg powder for concentrate for solution for infusion
    • EXBLIFEP®▼ (Cefepime / Enmetazobactam) 2 g/0.5g powder for concentrate for solution for infusion
    • GOBIVAZ®▼ (Golimumab) 50mg solution for injection in pre-filled pen;100mg solution for injection in pre-filled pen; 50mg solution for injection in pre-filled syringe
    • MYNZEPLI®▼ (Aflibercept) 40mg/mL solution for injection in a pre-filled syringe
  • Learning Lab 
    • Webinars
    • Digital Materials
  • Contact Us
Search
Search in all-demand content library:
Homepage /

Watch and Learn

Order by date

Newest Oldest

OCALIVA®▼(obeticholic acid) Mechanism of Action video

2025-10-09

Gain deeper insight into how Ocaliva works with our Mechanism of Action (MOA) video. This short educational video clearly explains Ocaliva's mechanism of action in primary biliary cholangitis (PBC), showing how it targets bile acid pathways to support improved liver function and patient outcomes. For prescribing information and adverse event reporting, click here


Dr Janine David _Understanding Testosterone Deficiency

2025-09-02

Helping Your Patients Restore Hormonal Balance with Confidence For prescribing information and adverse event reporting, click here


Adverse events should be reported. Reporting forms and information for the UK can be found at https://yellowcard.mhra.gov.uk/ and also report using the Yellow Card app. The app is available to download from the Apple App Store, or Google Play Store and you can use your Yellow Card website account details on the app to report. Adverse events should also be reported to ADVANZ PHARMA Medical Information via telephone on +44 (0) 208 588 9131 or via e-mail at medicalinformation@advanzpharma.com

VALIDATIONREFERENCE

This promotional website is intended for UK Healthcare Professionals. Any images are models and not real patients.

© 2025 ADVANZ PHARMA. All rights reserved.

Terms & Conditions Privacy & Cookies Notice Contact

Available room(s)

#{title}

#{text}

Confirmation

You are not log in.

You have to be log in to access this feature.

Log in
Meeting.

Click on continue to be redirected to the meeting video room.

Continue

Networking page access list